Clinical Trial Detail

NCT ID NCT04267887
Title Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

prostate cancer

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult senior

No variant requirements are available.